Semaglutide for Weight Loss: The Complete Evidence-Based Guide
Last updated: · Monthly refresh · Updated on every major trial publication
14.9%
Average weight loss (STEP 1)
68 wk
Trial duration (STEP 1)
17,604
Participants (SELECT trial)
Written by Alejandro Reyes
Founder & Lead Researcher
Reviewed by Peptide Nerds Editorial · Updated March 2026
Medical disclaimer: This guide is for educational purposes only and is not medical advice. Semaglutide is a prescription medication approved for specific indications. Always consult a qualified healthcare provider before starting any medication. See our full medical disclaimer.
In this guide
What is semaglutide?
Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk. It mimics the naturally occurring hormone glucagon-like peptide-1, which regulates appetite, blood sugar, and gastric emptying. It is the most widely prescribed and most extensively studied weight loss medication in history.
Semaglutide is sold under three brand names, each with a different indication and formulation:
- Wegovy (semaglutide 2.4 mg injection) -- FDA-approved for chronic weight management
- Ozempic (semaglutide 0.5 mg, 1 mg, or 2 mg injection) -- FDA-approved for type 2 diabetes
- Rybelsus (semaglutide 7 mg or 14 mg oral tablet) -- FDA-approved for type 2 diabetes
The molecule is identical across all three products. The differences are dose, route of administration, and regulatory approval. Wegovy is the only formulation specifically approved for weight loss.
Semaglutide works through two primary mechanisms. First, it activates GLP-1 receptors in the brain (particularly the hypothalamus) to reduce appetite and food cravings. Second, it slows gastric emptying, which increases feelings of fullness after smaller meals. The net effect is a sustained reduction in caloric intake without the constant hunger that undermines most diets.
For full compound data -- mechanism, pharmacokinetics, half-life -- see the semaglutide compound profile.
Weight loss results
The STEP trial program
Semaglutide's weight loss evidence comes primarily from the STEP (Semaglutide Treatment Effect in People with Obesity) trial program -- one of the largest clinical trial programs ever conducted for a weight loss medication. The headline result: 14.9% average body weight loss at the 2.4 mg dose over 68 weeks in STEP 1 (PMID: 33567185).
| Trial | Population | Weight Loss | Duration |
|---|---|---|---|
| STEP 1 | Obesity without diabetes | 14.9% | 68 weeks |
| STEP 2 | Obesity with type 2 diabetes | 9.6% | 68 weeks |
| STEP 3 | Obesity + intensive behavioral therapy | 16.0% | 68 weeks |
| STEP 5 | Obesity, 2-year follow-up | 15.2% | 104 weeks |
| SURMOUNT-5 | Head-to-head vs tirzepatide | 13.7% (vs tirz 20.2%) | 72 weeks |
Several things stand out. STEP 2 produced lower weight loss (9.6%) because type 2 diabetes makes weight loss physiologically harder. STEP 3 produced the highest weight loss (16.0%) because it combined semaglutide with intensive behavioral therapy -- diet counseling, exercise coaching, and regular check-ins. STEP 5 confirmed that weight loss is maintained at 2 years with continued treatment.
The SURMOUNT-5 head-to-head trial (PMID: 39652484) directly compared semaglutide to tirzepatide. Tirzepatide produced significantly more weight loss (20.2% vs 13.7%). This is the clearest evidence that the dual GLP-1/GIP mechanism outperforms GLP-1 alone for weight loss.
For the full week-by-week breakdown, see semaglutide weight loss results week by week. For what to expect in the first 3 months, see how much weight can you lose on semaglutide in 3 months.
Dosing schedule
Semaglutide for weight loss (Wegovy) follows a standardized 16-to-20-week dose escalation schedule. This gradual increase is critical for minimizing gastrointestinal side effects. Skipping ahead to higher doses does not produce faster weight loss -- it produces more nausea and vomiting.
| Dose | Duration | Notes |
|---|---|---|
| 0.25 mg/week | Weeks 1-4 | Initiation dose (not therapeutic for weight loss) |
| 0.5 mg/week | Weeks 5-8 | Some appetite suppression begins |
| 1.0 mg/week | Weeks 9-12 | Noticeable appetite reduction for most patients |
| 1.7 mg/week | Weeks 13-16 | Near-maintenance dose |
| 2.4 mg/week | Week 17 onward | Maintenance dose (full therapeutic effect) |
Semaglutide is administered as a once-weekly subcutaneous injection, typically in the abdomen, thigh, or upper arm. The injection site should be rotated each week. It can be taken at any time of day, with or without food, on the same day each week.
If a dose is missed, take it as soon as possible within 5 days. If more than 5 days have passed, skip the missed dose and resume the regular schedule. Do not double up.
For dosing tools, see our dosage calculator and reconstitution calculator.
Get the Peptide Starter Kit (free)
A quick-start guide to GLP-1 peptides, dosing basics, and what to ask your doctor.
Side effects
Semaglutide's side effect profile is dominated by gastrointestinal symptoms. These are a direct consequence of the GLP-1 mechanism and are most common during the dose escalation phase. The STEP 1 trial reported the following rates at the 2.4 mg dose:
| Side Effect | Rate (semaglutide) | Rate (placebo) |
|---|---|---|
| Nausea | 44% | 18% |
| Diarrhea | 30% | 16% |
| Vomiting | 24% | 6% |
| Constipation | 24% | 10% |
| Abdominal pain | 20% | 11% |
Most gastrointestinal side effects are mild to moderate and improve over time. In STEP 1, only 7% of participants discontinued treatment due to adverse events. The slow dose escalation schedule is specifically designed to reduce these effects. Eating smaller meals, staying hydrated, and avoiding high-fat foods during dose increases can help.
More serious but rare concerns include pancreatitis, gallbladder disease, and a potential signal for thyroid C-cell tumors (observed in animal studies but not confirmed in humans). Semaglutide carries a boxed warning for thyroid C-cell tumors based on rodent data, though no causal link has been established in humans.
For the full safety analysis, see semaglutide side effects: long-term safety data and GLP-1 side effects: what to expect. For concerns about muscle loss during treatment, see GLP-1 and muscle loss: what the research shows.
Semaglutide and hair loss
Hair loss is one of the most commonly searched concerns related to semaglutide. The clinical picture is nuanced. Hair loss was not identified as a frequent side effect in the STEP trials. However, anecdotal reports from patients and prescribers have been consistent enough to warrant attention.
The most likely explanation is telogen effluvium -- a temporary form of hair shedding triggered by rapid weight loss, nutritional changes, or physiological stress. This occurs with any form of significant weight loss (bariatric surgery, very low calorie diets, illness) and is not unique to semaglutide.
Telogen effluvium typically begins 2 to 4 months after the triggering event (in this case, rapid weight loss) and resolves on its own within 6 to 12 months as weight stabilizes. Adequate protein intake and nutritional supplementation may help, though evidence is limited.
For the full evidence review, see semaglutide and hair loss: what the evidence actually shows.
Alcohol and semaglutide
There is no formal contraindication between semaglutide and alcohol. However, combining them can amplify gastrointestinal side effects. Semaglutide slows gastric emptying. Alcohol irritates the stomach lining. Together, the result is often increased nausea, reflux, and discomfort.
Beyond GI effects, alcohol adds empty calories that work against the caloric deficit semaglutide creates. Alcohol also impairs judgment around food choices, which can undermine the behavioral changes that maximize semaglutide's effectiveness.
Most prescribers recommend limiting alcohol during treatment, especially during dose escalation. Some patients report that their desire for alcohol naturally decreases on semaglutide -- a finding that is being studied in ongoing alcohol use disorder trials.
For practical guidance, see can you drink alcohol on semaglutide?
Oral vs injectable semaglutide
Semaglutide is available in both injectable (Wegovy, Ozempic) and oral (Rybelsus) formulations. The oral version uses a co-formulation with SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) to enhance absorption through the stomach lining.
The key difference is bioavailability. Oral semaglutide has roughly 1% oral bioavailability, meaning the doses are much higher (7 mg and 14 mg daily) to achieve comparable blood levels to the injectable form (0.5 mg to 2.4 mg weekly). Rybelsus is currently approved only for type 2 diabetes, not weight management, though higher-dose oral formulations for obesity are in development.
Oral semaglutide must be taken on an empty stomach with no more than 4 ounces of plain water, then you must wait at least 30 minutes before eating, drinking, or taking other medications. This strict regimen is necessary for absorption and can be inconvenient for some patients.
For the full comparison, see oral semaglutide vs injectable: which is better for weight loss? and oral vs injectable semaglutide comparison.
Compounded vs brand-name semaglutide
The cost gap between brand-name semaglutide ($1,300+/month) and compounded semaglutide ($200-$500/month) has driven enormous demand for compounded versions. The difference matters because the regulatory framework is different.
Brand-name Wegovy and Ozempic are manufactured under strict FDA oversight with verified purity, potency, and sterility. Compounded semaglutide is prepared by compounding pharmacies under state pharmacy board oversight. 503B outsourcing facilities receive some FDA inspection; 503A pharmacies (traditional compounding) do not.
The FDA has issued multiple warnings about compounded semaglutide products, including instances of products containing semaglutide salt forms (like semaglutide sodium) that are not the same as the base molecule used in Wegovy and Ozempic. Potency, purity, and sterility vary between pharmacies.
If choosing compounded semaglutide, prioritize 503B outsourcing facilities that provide certificates of analysis (COA) with third-party testing verification.
For the full breakdown, see compounded vs brand-name semaglutide and tirzepatide, compounded vs brand semaglutide comparison, and compounded semaglutide protocol for beginners.
Cost
Semaglutide for weight loss (Wegovy) has a list price of approximately $1,300 per month without insurance. This is the single biggest barrier to access for most patients.
Insurance coverage varies widely. Medicare does not currently cover anti-obesity medications. Some commercial insurance plans cover Wegovy with prior authorization, though many require documented failure of lifestyle interventions and specific BMI thresholds. Employer-sponsored plans are increasingly adding coverage as evidence for long-term cost savings accumulates.
Novo Nordisk offers a savings program for commercially insured patients that can reduce out-of-pocket costs. For uninsured patients, compounded semaglutide ($200-$500/month) and clinical trial enrollment (free) are the primary alternatives. Telehealth platforms have also emerged as a lower-friction access point, though pricing varies.
The cost landscape is evolving rapidly. Patent litigation, compounding pharmacy regulation, international price comparisons, and potential CMS policy changes all factor into the near-term outlook for semaglutide pricing.
Semaglutide vs tirzepatide
The SURMOUNT-5 head-to-head trial settled the debate: tirzepatide produces significantly more weight loss than semaglutide (20.2% vs 13.7% at 72 weeks; PMID: 39652484).
The reason is mechanistic. Semaglutide targets one receptor (GLP-1). Tirzepatide targets two (GLP-1 + GIP). The additional GIP receptor activation improves metabolic efficiency and fat utilization in ways GLP-1 alone cannot. This is consistent with the broader pattern: more receptor targets produce greater weight loss (semaglutide < tirzepatide < retatrutide).
That said, semaglutide has important advantages. It has years more real-world safety data. The SELECT trial (17,604 participants; PMID: 37952131) demonstrated a 20% reduction in major adverse cardiovascular events -- the first obesity medication to prove cardiovascular benefit. That evidence base matters for prescribers and patients weighing long-term safety.
For the full comparison, see semaglutide vs tirzepatide. For other matchups, see semaglutide vs retatrutide, semaglutide vs liraglutide, Ozempic vs Wegovy, semaglutide vs survodutide, and semaglutide vs tesofensine.
Stay current on semaglutide research and access.
New trials, pricing updates, compounding news, and evidence reviews -- delivered weekly. No spam. Unsubscribe anytime.
Get the Peptide Starter Kit (free)
Quick-start guide to GLP-1 peptides, dosing basics, and what to ask your doctor.
All semaglutide content on this site
This hub aggregates every semaglutide article, comparison, and reference page on Peptide Nerds. Each article below also links back to this hub.
Core guides
- Semaglutide for Weight Loss: What the Evidence Shows
- Semaglutide Weight Loss Results Week by Week
- How Much Weight Can You Lose on Semaglutide in 3 Months?
Side effects and safety
- Semaglutide Side Effects: Long-Term Safety Data
- Semaglutide and Hair Loss: What the Evidence Shows
- Can You Drink Alcohol on Semaglutide?
- GLP-1 Side Effects: What to Expect
- GLP-1 and Muscle Loss: What the Research Shows
- Ozempic Face: What Causes It and How to Prevent It
- Semaglutide and Muscle Preservation: How to Keep Lean Mass
Formulations and access
- Oral Semaglutide vs Injectable for Weight Loss
- Compounded vs Brand-Name Semaglutide and Tirzepatide
- Compounded Semaglutide Protocol for Beginners
- Compounded Semaglutide Safety: Quality, Testing, and Red Flags
Comparisons (editorial)
- Semaglutide vs Tirzepatide
- Semaglutide vs Retatrutide
- Semaglutide vs Liraglutide
- Ozempic vs Wegovy
- Compounded vs Brand Semaglutide
- Oral vs Injectable Semaglutide
- Semaglutide vs Survodutide
- Semaglutide vs Tesofensine
Compound reference pages
Tools
Frequently asked questions
How much weight can you lose on semaglutide?
The STEP 1 trial showed an average of 14.9% body weight loss at the 2.4 mg dose over 68 weeks. For a 250-pound person, that is roughly 37 pounds. Individual results vary widely based on dose adherence, diet, exercise, and starting weight. Some participants in STEP 1 lost more than 20% of their body weight.
What are the most common side effects of semaglutide?
The most common side effects are gastrointestinal: nausea (44%), diarrhea (30%), vomiting (24%), and constipation (24%). These are most pronounced during dose escalation and typically improve over time. Most side effects are mild to moderate. Serious adverse events are rare but include pancreatitis, gallbladder disease, and potential thyroid C-cell tumor risk (observed in rodent studies).
How long does it take for semaglutide to work?
Most people notice weight loss beginning within the first 4 to 8 weeks. However, semaglutide follows a slow dose escalation schedule over 16 to 20 weeks before reaching the full 2.4 mg maintenance dose. Peak weight loss occurs around weeks 60 to 68. The drug works progressively -- early results underestimate the full effect.
Can you drink alcohol on semaglutide?
There is no absolute contraindication, but alcohol can worsen gastrointestinal side effects like nausea and vomiting. Semaglutide slows gastric emptying, which may intensify the effects of alcohol. Many physicians recommend limiting alcohol intake while on semaglutide, particularly during the dose escalation phase when GI side effects are most common.
Does semaglutide cause hair loss?
Hair loss (telogen effluvium) has been reported by some semaglutide users, but it was not identified as a common side effect in clinical trials. The more likely explanation is that rapid weight loss itself -- regardless of how it occurs -- can trigger temporary hair shedding. This typically resolves once weight stabilizes. It is not unique to semaglutide.
What is the difference between Ozempic and Wegovy?
Ozempic and Wegovy contain the same active ingredient: semaglutide. The difference is dosing and FDA-approved indication. Ozempic is approved for type 2 diabetes at doses up to 2 mg per week. Wegovy is approved for chronic weight management at doses up to 2.4 mg per week. The molecules are identical. The regulatory label and maximum dose are what differ.
Is compounded semaglutide safe?
Compounded semaglutide is not subject to the same FDA oversight as brand-name Wegovy or Ozempic. Purity, potency, and sterility can vary between compounding pharmacies. Some pharmacies produce high-quality compounded semaglutide; others do not. The FDA has issued warnings about certain compounded semaglutide products. If using compounded semaglutide, choose a 503B outsourcing facility that undergoes FDA inspection.
Do you regain weight after stopping semaglutide?
The STEP 4 trial showed that participants who stopped semaglutide after 20 weeks regained approximately two-thirds of their lost weight within one year. This is consistent with obesity being a chronic condition that requires ongoing treatment. Semaglutide does not cure obesity -- it manages it. Stopping the medication removes the appetite suppression and metabolic effects that produced the weight loss.
Sources
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM, 2021. PMID: 33567185
- Davies M, et al. Semaglutide 2.4 mg Once a Week in Adults with Overweight or Obesity, and Type 2 Diabetes (STEP 2). Lancet, 2021. PMID: 33667417
- Wadden TA, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy (STEP 3). JAMA, 2021. PMID: 33625476
- Rubino D, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA, 2021. PMID: 33752252
- Garvey WT, et al. Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5). Nature Medicine, 2022. PMID: 35585198
- Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). NEJM, 2023. PMID: 37952131
- Aronne LJ, et al. Tirzepatide Once Weekly for the Treatment of Obesity vs Semaglutide (SURMOUNT-5). NEJM, 2024. PMID: 39652484
Get the Peptide Starter Kit (free)
A quick-start guide covering GLP-1 peptides, dosing basics, side effect management, and what to discuss with your doctor.
Medical disclaimer: The information on this page is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. Semaglutide is a prescription medication -- consult a qualified healthcare provider before starting or changing any medication. Individual results vary. See our full medical disclaimer.